104 cells per well in round-bottomed, 96-well plates and incubated with effectors for 4 hours in triplicate. Supernatant (30 gi) was removed from each well and counted in a Betaplate scintillation counter (LKB-Wallac, Turku, Finland). Maximal counts, released by addition of 6 M HCI, and spontaneous counts released without CTLs were determined for each target preparation. Percent specific lysis was calculated as 100 x (experimental counts -spontaneous counts)/(maximal counts -spontaneous counts). 16 . 0. K. Rbtzschke et al., Nature 348, 252 (1990). 17 . L. A. Hawe et al., unpublished observations. 18. P. Vieira and K. Rajewsky, Ant. Immunol. 2, 487 (1 990). 19. J. J. Donnelly etal., J. Immunol. 145, 3071 (1990). 20. Female BALB/c mice 10 weeks of age were injected intraperitoneally with 0. (12) . Both the kinetics and efficiency of amplification of a target template are dependent on the starting abundance of that template and on the sequence match of the primers and target template and may also be affected by inhibitors present in the specimen (12). In PCR analysis of RNA samples, variable efficiencies in both the reverse transcription and amplification steps are potential sources of variability. For these reasons, comparison of the amount of specimen-derived PCR product to the amount of product from a separately amplified external control standard (11) does not provide a rigorous basis for absolute quantitation. Normalization based on coamplification of a heterologous "internal control" target sequence (such as P-globin or actin) does not optimally address this problem, owing to different template abundances and priming efficiencies for different primer-target combinations.
(TCID50) of ANHK/68 2 hours after serum injection, and a further injection of an equal amount of serum was given 3 days later. Mice were killed 6 and 7 days after infection, and viral lung titers in TCID50 per milliliter were determined as described (31) . 21 19, 3979 (1991). 30 . Abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, lie; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gin; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr. 31. T. M. Moran et al., J. Immunol. 146, 321 (1991 (10) or semiquantitative analyses (1 1) . In standard PCR methods, the absolute amount of product generated does not al-amount of target sequence present at initiation of the reaction, particularly for clinical specimens (12) . Both the kinetics and efficiency of amplification of a target template are dependent on the starting abundance of that template and on the sequence match of the primers and target template and may also be affected by inhibitors present in the specimen (12) . In PCR analysis of RNA samples, variable efficiencies in both the reverse transcription and amplification steps are potential sources of variability. For these reasons, comparison of the amount of specimen-derived PCR product to the amount of product from a separately amplified external control standard (11) does not provide a rigorous basis for absolute quantitation. Normalization based on coamplification of a heterologous "internal control" target sequence (such as P-globin or actin) does not optimally address this problem, owing to different template abundances and priming efficiencies for different primer-target combinations.
In the quantitative competitive PCR (QC-PCR) method for RNA quantitation (13) a competitive RNA template matched to the target sequence of interest, but differing from it by virtue of an introduced internal deletion, is used in a competitive titration of the reverse transcription and PCR steps, providing stringent internal control (13) (14) (15) . Increasing known copy numbers of competitive template are added to replicate portions of the test specimen, and quantitation is based on determination of the relative, not absolute, amounts of the differently sized amplified products derived from the wild-type and competitive templates, after electrophoretic separation. To increase the sensitivity and consistency of amplification of only virion-associated RNA, we pelleted virus from plasma by ultracentrifugation, used procedures intended to maximize recovery of extracted RNA (13) , and targeted a highly conserved sequence in HIV-1 gag (16), using oligonucleotide primers that incorporate neutral inosine residues at the few positions of recognized variability (13, 16, 17) .
Sixty-six consecutively enrolled HIV-1-infected subjects representing all stages of infection [Centers for Disease Control (CDC) stages I to IV] (2) and ten HIV-1 seronegative healthy donors were evaluated for virion-associated HIV-1 RNA by QC-PCR. Infected subjects were also tested for culturable virus and for p24 antigen with both standard and immune complex dissociation (ICD) test procedures, as described (13, (17) (18) (19) . For each subject, all virologic measurements were made with a single plasma sample, which was divided and frozen in replicate portions. Figure 1 illustrates QC-PCR results from a control reconstruction experiment, along with a representative experimental determination of plasma HIV-1 copy number for an infected patient. Virion-associated RNA was detected and quantified in plasma specimens from all 66 HIV-1-infected subjects (Table 1) . Determined RNA copy numbers ranged from 1.00 x 102 to 2.18 x 107 HIV-1 RNA copies per milliliter of plasma (corresponding to 0.50 x 102 to 1.09 x 107 virions per milliliter). Positive signals for wild-type HIV-1 target sequences were not observed in specimens from any of ten uninfected control subjects or, when the reverse transcription step was omitted, for specimens from any of the HIV-1-infected patients.
The threshold sensitivity for RNA QC-PCR analysis was determined to be 100 copies per reaction (13, 20) . Although positive signals could be detected for as few as 10 to 20 copies, results were less consistent below 100 copies per reaction, and quantitation was less reliable. QC-PCR analysis was typically performed with 0.5-ml plasma samples. However, pelleting the virus from increased volumes of plasma for specimens containing low numbers of virions did allow for increased overall sensitivity of detection. Thus, for one p24 antigennegative, culture-negative CDC stage II patient (patient TIMI 0852, Table 1 ), initial QC-PCR analysis of a 0.5-ml specimen portion gave a negative result. However, analysis of virus pelleted from 2.8 ml of a replicate plasma sample allowed unequivocal detection of the low amount of virus present in this patient's plasma (100 copies per milliliter), whereas no HIV-1 RNA was seen with analysis of comparable volumes of plasma from HIV-1 seronegative controls. In separate control studies, analysis of triplicate portions of plasma samples from six different patients, with mean HIV RNA copy numbers of 6.7 x 104 to 1.0 x 106 per milliliter, gave a mean SD of 22%. Analysis of replicate portions of the same HIV-1 RNA preparation on six different days gave an SD of 15%. This reproducibility contrasts with variability of up to 600 to 1000% reported for noncompetitive PCR procedures (11, 12, 14) .
Whereas the QC-PCR method quantified virion-associated HIV-1 RNA in all 66 patients tested, virus culture and standard p24 antigen assays were much less sensitive, with positive results in 4/20 and 5/20 subjects with CD4' T cell counts >500 per cubic millimeter, 6/18 and 7/18 subjects with CD4' T cell counts of 200 to 500 per cubic millimeter, and in 22/28 and 24/28 subjects with CD4+ cells fewer than 200 per cubic millimeter, respectively (Table  1 ). In 30 patients with negative results in standard p24 antigen assays, the use of acid treatment to dissociate p24 from immune complexes increased the frequency of detection by only four patients, although absolute measured amounts of p24 were increased in 25/36 patients with detectable levels of p24 before acid treatment.
QC-PCR-determined HIV-1 RNA levels in plasma differed between clinical stages, with levels for CDC stage II (2) . #Three days previously, plasma cultures were positive at 10 TCID/ml, with HIV-1 RNA level of 1,350,600 copies/mI. **Eight days previously, plasma cultures were positive at 1,000 TCID/ml, with HIV-1 RNA level of 216,400 copies/mI (Fig.  2.) tFor kinetic analysis of viral load by RNA QC-PCR over a 6-week period of treatment with AZT, patients were studied before initiation of treatment (week 0), after 1, 2, and 6 weeks of treatment, and 1 week after temporary discontinuation of treatment (week 7). cell counts argue strongly for a direct role for HIV-1 replication in the pathogenesis of HIV disease. These results confirm and extend work by Coombs (5), Ho (5) , Pantaleo (9) , Schnittman (31) , and Michael (32) who, by alternative approaches, also found evidence of continuous viral replication related to clinical stage and disease progression. The finding of a large proportion of circulating virus that is not culturable raises the possibility that genetically defective (30) or otherwise noninfectious virus may contribute importantly to HIV-1 pathogenesis, in keeping with precedents in animal retrovirus systems (33) . Numerous mechanisms by which noninfectious particles might contribute to the pathogenesis of HIV-1 infection have been proposed (34) . Furthermore, recent observations have documented the presence of HIV-1-reactive cellular immune responses in patients who have been exposed to HIV-1 by sex or use of shared needles but who are not demonstrably infected with the virus (35) . Exposure to an inoculum consisting largely of noninfectious particles might produce such a result, even without the establishment of productive infection of the exposed individual.
Finally, our data suggest that determination of virion-associated HIV-1 RNA levels in plasma by QC-PCR represents a marker of viral replication with potential for widespread applicability in assessment of the activity of antiretroviral therapy. There is currently a widely recognized need for new markers that allow timely assessment of the in vivo antiviral activity of new therapeutic approaches and agents and that better predict the ultimate clinical efficacy of new treatments (36) . Ideally (13) and were designed to amplify an internal fragment of either 260 bp (from wild-type HIV-1 target sequences) or 180 bp (from the pQP1A80 competitive template). To maintain equivalent and competitive priming efficiency with divergent sequences, primers incorporated inosine residues at the few positions where divergence from the conserved consensus sequence has been reported (13, 16) . For QC-PCR analysis, two plasmids were prepared, one containing the target sequence (pQP1) and the other containing the identical sequence except for an 80-bp internal deletion (pQP1A80), sufficient to allow the derived PCR products to be readily resolved by electrophoresis (13) . In vitro RNA transcripts were prepared with commercially available kits. Final preparations in water were determined to be essentially free of degradation products by Northem (RNA) blot analysis and were quantified by measurement of absorbance at 260 nm. Portions were stored at -70'C until needed. PCR reaction conditions and protocols were generally similar to those found in commercially available kits (Perkin-Elmer, Norwalk, CT). Each test sample was divided into eight replicate portions and analyzed in the presence of o to 50,000 copies per reaction of competitive template. The initial reaction was performed in a total volume of 30 gi and contained 5 gi of test RNA (corresponding to 5% or less of the total specimen), 5 Fl of competing RNA preparation or water, and 30 U of cloned Moloney virus reverse transcriptase (BRL, Bethesda, MD). One portion from each specimen was analyzed without reverse transcription and in the absence of competitive template. After 10 min at room temperature to allow for partial extension and stabilization of random hexamer primers, conversion of RNA into cDNA was allowed to continue for 30 min at 42"C. This reaction was then adjusted to contain primers and additional buffer in a total volume of 60 jil. Amplification was performed as described (13), with 45 cycles (940C for 1 minm 50MC for 2 min, and 72"C for 1 min), followed by a final incubation at 5'C for 5 min. After amplification, approximately 7% of each reaction product mixture was separated by electrophoresis in composite 2% Synergel (Diversified Biotech, Newton Center, MA)-1% agarose (FMC Bioproducts, Rockport, ME) gels in 20 mM tris acetate (pH 7.8) and 1 mM EDTA. Gels were stained with ethidium bromide for visualization under ultraviolet illumination. Quantitation of fluorescence of both wild-type and competitive template product bands was performed on a Lynx 4000 molecular biology workstation with matched custom software (Applied Imaging, Santa Clara, CA), as described (13) . Competition equivalence points were determined by interpolation on plots of the logarithm of the calculated ratio of signal for the competitive template-derived product over the signal for the wild-type target sequence-derived product (corrected for molar ratio) versus the logarithm of the copy number of added competitive template ( Fig. 1) (13 
